B. Riley Analysts Increase Earnings Estimates for InfuSystem

Key Points

• Analysts at B. Riley have raised their Q3 2025 EPS estimate for InfuSystem Holdings to $0.10 per share, significantly up from their prior forecast of $0.02, and maintain a "Strong-Buy" rating.
• InfuSystem's full-year earnings consensus estimate is currently $0.15 per share, with projected future earnings of $0.30 EPS for FY2025 and $0.45 EPS for FY2026.
• Institutional investors control approximately 71.13% of InfuSystem's stock, with significant increases in positions by several firms during the second quarter.

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Analysts at B. Riley increased their Q3 2025 earnings per share estimates for InfuSystem in a report issued on Tuesday, August 5th. B. Riley analyst A. Schock now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their previous estimate of $0.02. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem's Q4 2025 earnings at $0.09 EPS, FY2025 earnings at $0.30 EPS, Q3 2026 earnings at $0.16 EPS and FY2026 earnings at $0.45 EPS.

A number of other analysts have also recently commented on INFU. Roth Capital started coverage on InfuSystem in a research report on Tuesday, July 22nd. They set a "buy" rating and a $12.00 price objective for the company. Wall Street Zen cut InfuSystem from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 14th.

InfuSystem Price Performance

INFU stock traded up $0.61 during midday trading on Friday, hitting $9.21. 306,075 shares of the stock were exchanged, compared to its average volume of 161,590. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The stock's 50-day moving average price is $6.16 and its 200-day moving average price is $6.15. The stock has a market cap of $188.14 million, a price-to-earnings ratio of 153.54 and a beta of 1.81. InfuSystem has a fifty-two week low of $4.61 and a fifty-two week high of $9.97.

Institutional Investors Weigh In On InfuSystem

Several institutional investors and hedge funds have recently modified their holdings of the stock. Truffle Hound Capital LLC purchased a new stake in shares of InfuSystem in the second quarter worth about $1,123,000. Integrated Quantitative Investments LLC purchased a new stake in shares of InfuSystem in the second quarter worth about $243,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of InfuSystem by 38.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,772 shares of the company's stock worth $435,000 after buying an additional 19,554 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of InfuSystem in the second quarter worth about $294,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of InfuSystem in the second quarter worth about $135,000. Hedge funds and other institutional investors own 71.13% of the company's stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.